Verastem, Inc. (VSTM) Dividend History

Company News

• Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

  The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.

  Benzinga

  Featured Companies: ALXO CRDF EXEL ONCY
• Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

  Enphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.

  Benzinga

  Featured Companies: ALLR ATCH AZTR CJET DRMA ENPH NIVF PMNT RGC SFL SOAR STX TSLA UP
• Verastem, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire

  The Portnoy Law Firm has initiated an investigation into Verastem, Inc. (NASDAQ: VSTM) for potential securities fraud after the company disclosed serious adverse events in a clinical trial, causing a significant drop in its stock price.

  GlobeNewswire Inc.
• Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)

  Verastem Oncology is on track to secure a drug approval for avutometinib, but their low cash position poses a significant risk. Find out why VSTM stock is a Buy.

  Seeking Alpha
• Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data

  Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.

  Zacks Investment Research

  Featured Companies: ALXO ANVS ENTX